Releasing Nuclear Medicine Patients to the Public

Releasing Nuclear Medicine Patients to the Public

Educational Objectives • Introduce participants to the medical conditions that are Releasing Nuclear Medicine treated with radioiodine. • Review the regulatory considerations regarding Patients to the Public: inpatient and outpatient radioiodine procedures. Dose Calculations and Discharge • Review ways in which the regulatory requirements may be satisfied, including “public” radiation dose Instructions computations, content of post-discharge instructions and addressing the concerns of patients and their families. Robert E. Reiman, MD Radiation Safety Division • Introduce Web-based methods to facilitate Duke University Medical Center documentation of outpatient treatment. Durham, NC Medically Useful Iodine Isotopes Treatment of Toxic Goiter Isotope Half-life Primary Use Emissions I-123 13.3 hours γ (0.158 MeV) Diagnosis • Surgery (not done, except for very large thyroid, low iodine uptake, cancer or I-124 4.2 days β+ and γ (0.511 Diagnosis, pregnancy) MeV +) Therapy(?) I-125 59.4 days γ (0.035 MeV) Brachytherapy • Drugs (propylthiouracil) and beta blockers (short-term) I-131 8.0 days β- (0.606 MeV), Diagnosis, • Ablation with radioactive iodine γ (0.364 MeV) Therapy Radioiodine Treatment Thyroid Carcinoma • I-131 sodium iodide solution, orally • 8 – 15 millicuries for diffuse toxic goiter • Incidence: about 3 per 100,000 per year • 15 – 40 millicuries for toxic multinodular • Females > Males (2:1) goiter • About 80% papillary type; remainder • Must know the % uptake at 24 hours to follicular or medullary types. compute administered activity and • Medullary thyroid carcinoma does not clearance rates take up radioiodine. 1 Diagnosis of Thyroid Treatment of Thyroid Carcinoma Carcinoma • Surgical removal of thyroid gland and • Usually asymptomatic except for a dissection of local lymph nodes. painless neck mass. • Total body diagnostic I-131 scan after • “Cold” nodule on Tc-99m pertechnetate withdrawal of thyroid hormone to detect scintigraphy. metastatic disease. • Non-cystic mass on ultrasound. • I-131 sodium iodide, 150 – 200 millicuries • Fine needle aspiration of nodule. administered orally to ablate remaining thyroid and metastases. “Neuroendocrine” Tumors Carcinoid Tumors • Carcinoid Tumors • Incidence: About 25 / million / year • Most arise somewhere in the GI tract • Pheochromocytoma (75%) or lungs (25%). • Usually small and do not cause • Neuroblastoma (mainly children) symptoms (benign). • Medullary Thyroid Carcinoma • Malignant ones can metastasize to liver, bone and lung. Treatment of Carcinoid Non-Hodgkin’s Lymphoma Syndrome • Surgery • Incidence: About 200 / 100,000 per year in U.S (7 – 8 times more common than • Embolization of liver metastases Hodgkin’s Disease) • Average age at diagnosis: 60 • I-131 MIBG • Diffuse disease involving lymph nodes • Yttrium-90 Octreotide and bone marrow • B-cell and T-cell types 2 Treatment of Non-Hodgkin’s Treatment with I-131 MAB Lymphoma • External beam irradiation of mantle field • Serial images with I-131 MAB (5 mCi) to and/or pelvic lymph nodes determine total body clearance half-time. • Titrate administered therapy activity • Chemotherapy based on clearance half-time. • Immunotherapy with monoclonal • Precede I-131 MAB with infusion of non- antibodies against B-cells (MAB) labeled MAB. • Radioimmunotherapy: I-131 MAB or Y-90 • Administer 80 – 120 mCi via slow MAB intravenous infusion. The Reasons We Have Release I-131 Patient Release: Regulations Are... History • Prior to 1997, criteria for release were • To ensure that radiation exposure to based strictly upon activity or dose-rate. the public is ALARA. • OK to Release if: < 30 millicuries, or < 5 • To reassure concerned members of mrem per hour at one meter. the public that the “risk” from • After 1997, criteria based upon expected radiation patients is manageable and radiation dose to a “member of the under authoritative control. public” being < 500 millirem. Current Regulatory Criteria Current Regulatory Requirements • Written Instructions on minimizing • Criteria are “risk-based” rather than exposure to others must be provided to “rules-based”. patient if a member of the public could • Can be adapted to other therapeutic receive > 100 mrem. radionuclides, not just I-131. • Patient may be released if “public dose”, • Flexible approach to determination of as demonstrated by “default criteria” or expected dose to public. by licensee’s computation, is < 500 mrem. 3 Current Regulatory Where to Find Regulations and Requirements Regulatory Guidance • Written Documentation of release is • 10 CFR 35.75 , “Release of Individuals Containing Unsealed Byproduct Material or Implants Containing required if licensee’s computation is Byproduct Material”. based on assumptions other than – www.nrc.gov > Electronic Reading Room > Regulations (10 CFR) those underlying the “default criteria”. • NUREG 1556, Vol. 9, Appendix U (formerly Regulatory Guide 8.39) • Documentation must be maintained – www.nrc.gov > Electronic Reading Room > Document by the licensee for three years. Collections > NUREG-Series Publications “Default” I-131 Release “Default” I-131 Release Criteria Criteria • < 33 millicuries administered, or < 7 D = 1.44 x T1/2 x O x R mrem/hr at one meter Æ FREE TO GO. Need only written instructions (generic; D= “Public” dose T1/2 = physical half-life (hr) provided by Nuclear Medicine). O = Occupancy factor at one meter • Based on: patient is an unshielded R = Dose rate at one meter (mrem/hr) point source, and only elimination is by For T1/2 = 196 hr, O = .25 and R = 7 physical decay (conservative). mrem/hr, D = 500 mrem. Licensee’s Computation Licensee’s Computation ∞ D = O ⌠ R(t) dt ⌡0 • May assume non-point source geometry. I-131 MIBG Clearance 1.2 • May assume tissue shielding. 1.0 y = 0.8061e-0.0229x 0.8 R2 = 0.9253 • May take biological clearance into 0.6 account. Fraction 0.4 0.2 • May assume occupancy factor different R(t) at 1 m 0.0 0.0 50.0 100.0 150.0 than 0.25 at one meter. Hours Post-administration 4 External Dose From a What About Internal Thyroid Cancer Patient Irradiation? D = O ( 1.44 T1/2 R0 ) • Radioiodine from therapy patients may be D= “Public” dose excreted in their urine, perspiration and saliva. T1/2 = effective half-life (hr) O = Occupancy factor at one meter • These body fluids can contaminate household R0 = Dose rate at one meter (mrem/hr) surfaces. For T = 18 hr, O = 0.25 and R = 12 • Family members might ingest this R 1/2 0 mrem/hr, D = 97 mrem. contamination through hand-to-mouth contact. What About Internal Instructions Should Irradiation? Address... • Public transportation. • Assume one part in 100,000 of the radioactivity • Children, pregnant women and administered to patient (AA) is ingested by a nursing mothers. family member. • Spouse or spousal equivalent. • Compute effective dose to family member from ingestion: D = 10-5 (AA) (53 rem/mCi) • Visitors and co-workers. • If greater than 10% of computed external dose, • Time-Distance considerations. must include it in total dose computation. • Length of time to limit interaction. For Example... How Long Should Patients Limit Interaction? • Avoid airplanes and buses at first. • Limit interactions with others. • The higher the computed “general • Stay six feet or more away from public” dose, the longer the time children and pregnant women. certain activities should be avoided. • Spouse sleeps in a separate bed. • Times to avoid certain activities can • Use separate bathroom. be calculated based on the estimated “public dose”. • Shower / brush teeth frequently. 5 Maintaining Release Records Release Record Must Include... • No record required if patient released according to default criteria (< 33 mCi or • Patient identifier (NOT Name). 7 mrem/hr at one meter). • Release activity and dose rate at one meter. • Otherwise, release must be documented, • Survey instrument used. • Estimated “public” dose (mrem). and the documentation maintained for • Effective half-life used in computation of dose. three years. • Method used to compute dose. • Specific information regarding the • Times to limit certain activities. release must be included. Duke’s Implementation of The Radiation Safety Tech... Release Regulations • Interviews the patient to determine home • Uses initial dose rate at one meter. situation, transportation, work, visitors and • Uses Duke population clearance curves for capacity for self-care. different treatments. • Obtains dose rate measurement at one meter • Data for a patient is entered into a Web site. from patient • Web site calculates expected “general public” • Uses Web site to create “customized” dose and creates a set of instructions and instructions and release documentation. documentation. • Maintains documentation for three years. Alternative to Web Site What About Homeland Security? • Extremely sensitive radiation detectors are deployed in train stations, airports, tunnels, • Interview patient, obtain effective half-life and etc. measure dose rate. • I-131 patients may set off alarms up to 95 days • Look up “public dose” in pre-computed following a procedure.* tables and release patient if < 500 millirem. • Society of Nuclear Medicine recommends • Look up length of time instructions are to be giving patients letter containing radionuclide followed in tables. and hospital contact information. • Fill in pre-printed instruction form. *Zukier LS, Stabin M, Garetano G, Monetti M, Lanka V. Presented at Annual Meeting of RSNA, 30 November 2004. 6.

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    6 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us